Please assess the completion status of the following clinical trial:

Trial Title: Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Stratum 1:~  * Diagnosis of neurofibromatosis 1 (NF1) and plexiform neurofibromas~ * At high risk for progression, as defined by any of the following:~    * Anatomic location such that progression carries a high risk of impairment of function, pain, or disfigurement (e.g., neck/mediastinum, paraspinal nerve roots, orbit, and face)~   * Tumors that the patient, family, or caregiver believes have increased in size within the past year, but appear stable by standard clinical or radiographic measures~ * No plexiform neurofibromas that are small, cause no pain or functional impairment, or are not likely to cause pain or functional impairment over the succeeding 12 months~* Stratum 2:~  * Diagnosis of NF1 and progressive plexiform neurofibromas~    * Neurofibroma progression documented by increase in lesion size on MRI~ * Currently being enrolled on a clinical therapeutic trial at Children's Hospital of Philadelphia~PATIENT CHARACTERISTICS:~Age~* 25 and under~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Negative pregnancy test~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Stratum 1:~  * No prior or concurrent chemotherapy~ * No concurrent enrollment on a chemotherapy clinical trial~* Stratum 2:~  * At least 4 weeks since prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* At least 6 weeks since prior radiotherapy (stratum 2)~Surgery~* Prior surgery for progressive plexiform neurofibroma allowed if incompletely resected and measurable disease remains (stratum 2)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- 18FDG-PET scan and MR perfusion (Type: EXPERIMENTAL): Subjects will undergo MRI for quantitative (2D and 3D) evaluation of plexiform neurofibroma size, MR perfusion scan, and fludeoxyglucose (18FDG) PET scan at the time of study entry. Subjects who are treated for plexiform neurofibroma will undergo another 18FDG PET scan after one year of study entry.

Based on this trial design, predict the completion outcome and termination type (if applicable).